Background
Since the first-in-man transcatheter aortic valve implantation (TAVI) in 2002, many registries have shown that TAVI can be accomplished in non-operable and high-risk patients with outcomes that compare favourably with surgical aortic valve replacement [1] [2] [3] [4] [5] [6] [7] [8] . This has been observed with the two devices currently in use: the balloon-expandable Edwards SAPIEN (Edwards Lifesciences LLC, Irvine, CA, USA) and the self-expandable Medtronic CoreValve (Medtronic CV, Irvine, CA, USA) prostheses.
The first-generation balloon-expandable valve (Edwards SAPIEN) required 22 F and 24 F sheaths for the 23-and 26-mm valve sizes, respectively, for transfemoral insertion using the RetroFlex TM delivery system. The large sheath size was the most important limitation of this technique. Since October 2009, subsequent technical and procedural improvements have allowed the development of a new generation of balloon-expandable valves such as the Edwards SAPIEN XT, which decreased the required sheath size to 18 F and 19 F, respectively, using the NovaFlex TM delivery system.
Using the SAPIEN valve, the pivotal randomized Placement of Aortic Transcatheter Valve Trial US (PARTNER-US) trial demonstrated the superiority of TAVI over standard care, with a marked reduction in the mortality rate at 1 year in non-surgical candidates and a similar rate of survival at 1 year with TAVI and surgical aortic valve replacement in high-surgical-risk patients [9, 10] . Only limited data, however, are available for the Edwards SAPIEN XT valve [11, 12] . Thus, we sought to compare 30-day clinical outcomes in our prospective registry using Edwards SAPIEN XT and SAPIEN prostheses.
Methods

Patient selection and evaluation
Between May 2006 and October 2011, consecutive highrisk patients underwent TAVI using balloon-expandable Edwards prostheses, and were included in a prospective, single-centre registry. All patients had severe, degenerative symptomatic aortic stenosis. The indication for TAVI was based on the decision of the medicosurgical team. The patients were considered candidates for TAVI when their logistic EuroSCORE was greater or equal to 20%, in case of frailty, or in case of comorbidities contraindicating surgical aortic valve replacement. All patients provided signed informed consent for subsequent data collection and analysis for research purposes.
The screening process included transthoracic echocardiography (TTE), selective coronary angiography, aortography, iliofemoral angiography and computed tomography (CT) of the aorta and iliofemoral access. Transoesophageal echocardiography was not used in our institution to assess aortic annulus diameter. All patients with unstable haemodynamics were stabilized with balloon aortic valvuloplasty (BAV) before TAVI.
An annulus diameter of 18-21 mm was considered appropriate for the 23-mm prosthesis and 21-24 mm for the 26-mm prosthesis. In cases of borderline sizes (20.5-21.5 mm), aortography was performed during balloon predilatation with a 23-mm balloon, and the optimal valve size was selected based on the presence or absence of aortic regurgitation at full balloon inflation.
CT was crucial to assess the feasibility of a transfemoral approach. A minimum diameter of 7 and 8 mm was required for the 23-and 26-mm SAPIEN valves, respectively, and 6 and 6.5 mm for the 23-and 26-mm SAPIEN XT valves, respectively. Before percutaneous implantation, tortuosities, as well as the absence of calcified plaque at the area of femoral puncture site, were assessed to confirm the suitability for a femoral approach.
Devices
The procedures were performed using the SAPIEN valve ( (Fig. 1B) thereafter. The SAPIEN valve (Fig. 1A) is made of three bovine pericardial leaflets, matched for elasticity and thickness, sewn onto a stainless steel stent frame partially covered with a synthetic polyethylene terephthalate fabric sealing cuff. The prosthesis is crimped directly onto the balloon of the RetroFlex TM delivery system (Fig. 1C ), the outer diameters of which are 8.4 and 9.2 mm for the 23-and 26-mm SAPIEN valves, respectively. The SAPIEN XT valve (Fig. 1B) is made of a cobalt chromium frame with thinner struts and a more open cell structure to allow tighter crimping. The valve is crimped over the shaft of the 
NovaFlex
TM delivery system (Fig. 1D) and mounted on the balloon after introduction into the abdominal aorta. The NovaFlex TM delivery system allows a reduction in sheath size to 18 F (outer diameter 7.2 mm) and 19 F (outer diameter 7.5 mm) for the 23-and 26-mm valve sizes, respectively.
Patient preparation and procedure
Cardiac catheterization and premedication
All procedures were performed in a conventional cardiac catheterization laboratory with sterile precautions, using local anaesthesia and conscious sedation in all cases. Surgical arterial cut-down was performed by our cardiac surgeon for SAPIEN implantation, whereas most cases were performed using a percutaneous approach with pre-closing for SAPIEN XT implantation. For the latter approach, the cardiac surgeon was not always present. All of the equipment was present and ready to use in the catheterization laboratory, and both the anaesthesiologist and the echocardiographer were immediately available in the event of any complication.
Patients were preloaded with aspirin (160 mg) and clopidogrel (300 mg), and continued clopidogrel (75 mg) for 1 month and aspirin (75-160 mg) indefinitely. Heparin (5000 IU) was administered immediately after surgical cutdown or placement of the vascular closure device.
Local anaesthesia and sedation
Lidocaine 2% (20-30 mL) was used for local anaesthesia, injected into the skin and subcutis, and around the femoral artery for percutaneous and surgical approaches. Additional doses of lidocaine could be administered at any time during the procedure at the discretion of the operator. Conscious sedation consisted of intravenous administration of midazolam (1 mg) and nalbuphin (5 mg) at the start of the procedure. Additional half or full doses of each could be administered at the discretion of the operator during the course of the procedure.
Procedure
The techniques of SAPIEN and SAPIEN XT valve implantation have been described in detail elsewhere [9] [10] [11] . Briefly, in our centre, supravalvular aortography was performed to select the optimal view, aligning all cusps in a single plane. The selected femoral artery was cut-down or 'pre-closed' with a 10 F Prostar XL TM (Abbott Inc., Chicago, IL, USA). After crossing the aortic valve, a 260-cm long 0.035 inch Amplatz Extra-Stiff J-tip guidewire (COOK, Bjaeverskov, Denmark) was placed in the left ventricle. BAV was performed with rapid ventricular pacing (180-220 beats/min) using a 20-or 23-mm balloon in accordance with the valve size. Valve positioning was based on fluoroscopy, using annular calcification as a landmark, and serial (5-10 mL) supra-annular aortography to validate the position of the valve during rapid ventricular pacing. The prosthesis was also delivered using rapid ventricular pacing. Removal of the sheath was cautiously achieved with serial contralateral angiograms to detect iliofemoral complications. The femoral arteriotomy was then closed surgically or using the Prostar device. In the absence of a new left bundle branch block or atrioventricular block, the pacing lead was removed at the end of the procedure. Patients were monitored in the intensive care unit for 24 hours after valve implantation.
Data collection
Data on clinical and TTE variables were obtained at baseline, discharge and 1 month, and were entered into our institutional database. In patients from remote institutions, outcomes at 30 days were obtained by telephone interviews of the referring physician and exchange of TTE reports. No patients were lost to follow-up.
Endpoint definitions
The safety endpoint was a combination of all-cause mortality, major stroke, life-threatening bleeding, stage 3 acute kidney injury (AKI), periprocedural myocardial infarction, major vascular complication, and repeat procedure for valve-related dysfunction at 30 days. All complications were reported according to the Valve Academic Research Consortium (VARC) classification [13] .
Other endpoints included: device success according to the VARC definition (i.e. successful vascular access, delivery and deployment of the device, successful retrieval of the delivery system with correct position of the device, post-TAVI aortic valve area greater than 1.2 cm 2 and mean aortic valve gradient less than 20 mmHg or peak velocity less than 3 m/s without moderate or severe prosthetic valve regurgitation), New York Heart Association heart failure functional class, transvalvular mean pressure gradient, effective aortic valve area, presence and severity of aortic valvular regurgitation, and/or mitral valve regurgitation on TTE.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range), according to the distribution. Categorical variables are presented as frequencies and percentages. We used student's t test or the Manfred-Whitney test to compare differences between continuous variables, and the Chi-square or Fisher's exact test to compare differences between categorical variables, as appropriate. Differences were considered statistically significant at P values less than 0.05. All statistical analysis was performed using SPSS Statistics software version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
During the study period (May 2006 to October 2011), 250 patients underwent TAVI at our centre, all using balloonexpandable Edwards prostheses. A transapical access was used in 60 patients (24%), while 190 (76%) procedures were performed using a transfemoral access. Thus, the current study cohort comprised 190 patients who underwent transfemoral implantation of an Most patients underwent TAVI for severe, degenerative symptomatic aortic stenosis, but two patients in the SAPIEN XT group had a degenerated stenotic aortic bioprosthesis. Baseline clinical characteristics are shown in Table 1 . The mean Logistic EuroSCORE was significantly lower in the SAPIEN XT group (18.1 ± 11.0% vs 27.3 ± 11.1%; P < 0.0001).
History of myocardial infarction, coronary artery bypass graft and BAV were also significantly less frequent in the SAPIEN XT group. Patients treated with SAPIEN XT had a significantly smaller minimal luminal diameter of the access iliofemoral arteries than those treated with the SAPIEN prosthesis ( Table 1 ). All other variables were comparable between the two groups.
Baseline TTE data (Table 2 ) confirmed the severity of aortic stenosis in both groups. Mean aortic gradient was significantly higher in the SAPIEN XT group, probably because more patients in the SAPIEN group were previously treated by BAV. Left ventricular ejection fraction was also significantly higher in the SAPIEN XT group. However, the proportion of patients with left ventricular ejection fraction less than 30% was not significantly different in the two groups.
Periprocedural outcomes
Sedation and local anaesthesia, used in all cases, was well tolerated in both groups. The percutaneous approach was performed in most patients, apart from two in the SAPIEN XT group.
The prosthesis was placed in the appropriate position in all cases with successful vascular access. A single valve was implanted in 189 out of 190 cases (99.5%) ( Table 3) ; and there was no valve embolization. One patient of the SAPIEN XT group had an annulus rupture with tamponade requiring a valve-in-valve procedure. Transient haemostasis was obtained, but the patient died in the catheterization laboratory.
Conversion to emergent cardiac surgery was required in three patients (1.6%), all in the SAPIEN group (one aortic dissection, one aortic annulus rupture with tamponade and one major aortic regurgitation) ( Table 3 ). Conversion to general anaesthesia in the cardiac catheterization laboratory before transfer to the operating room occurred in one patient (annulus rupture) ( Table 3) . Two patients (aortic dissection and annulus rupture [mentioned above]) did not survive surgery. In contrast, in the SAPIEN XT group, conversion to general anaesthesia in the catheterization laboratory or conversion to cardiac surgery was never required (Table 3) . Urgent vascular surgery was required in seven cases (3.7%), with no significant difference between the two groups (5.1% vs 2.7%; P = 0.45).
Haemodynamics remained remarkably stable at each step of the procedures. Vasopressors were required in 11 patients (5.8%), including those requiring general anaesthesia described above and patients who had prolonged hypotension after valve delivery, without significant difference between the two groups (Table 3) . Procedural duration was significantly shorter in the SAPIEN XT group, whereas contrast volume was significantly greater in this group (Table 3) , due to additional use of contrast associated with the 'pre-close' technique.
The overall procedural device success rate was 94.7%, and was similar with the two valves (Table 3) . Procedural failure was related to: unsuccessful vascular access in three cases (two SAPIEN and one SAPIEN XT); a second valve implantation (SAPIEN XT); and severe aortic regurgitation (≥ grade 3) in six cases (three in each group).
Thirty-day safety outcomes
Thirty-day safety outcomes are shown in Table 4 . In the overall population, the combined 30-day safety endpoint was reached in 16.3%, including death (6.3%), major stroke (2.1%), life-threatening bleeding (8.9%), stage 3 AKI (0.5%), major vascular complication (7.9%), periprocedural myocardial infarction (2.1%), and repeat procedure for valve-related dysfunction (1.6%), with no significant difference between groups (Table 4) . We observed a similar, low rate of major stroke and periprocedural myocardial infarction in both groups. Life-threatening and major bleedings were not significantly different between the groups (Table 4 ), but minor bleeding was more frequent in the SAPIEN XT group (8.0% vs 1.3%; P = 0.049). However, the need for blood transfusion showed a trend for a lower rate in the SAPIEN XT group (21.4% vs 33.3%; P = 0.07).
Major vascular complication occurred in six patients (7.7%) in the SAPIEN group, related to vascular rupture requiring urgent surgery in four cases and to aortic dissection in two cases (one requiring unsuccessful urgent cardiac surgery and one managed medically without death). Major vascular complication occurred in nine patients (8.1%) in the SAPIEN XT group, all related to failure of the vascular closure devices, requiring endovascular stent graft in six patients and prolonged manual compression in three cases. There was a trend towards a higher rate of minor vascular complication in the SAPIEN XT group (18.9% vs 9.0%; P = 0.058; Table 4 ). A permanent pacemaker was required in 5.9% of the overall population, with no significant difference between the groups. Finally, median hospital stay was significantly shorter in the SAPIEN XT group (5.5 vs 8.0 days; P < 0.001; Table 4 ).
Prosthesis performance
New York Heart Association heart failure functional class was dramatically improved at 30 days (Table 5 vs Table 1 ). Haemodynamic variables, aortic valve area and mean aortic gradient were also markedly improved (Table 5 vs Table 2 ). Moderate to important aortic regurgitation was infrequent (≥ grade 3 in 3.7%). Overall, results were similar in the SAPIEN and SAPIEN XT groups. 
Discussion
The main findings of this study are: (1) introduction of the SAPIEN XT valve and NovaFlex TM delivery system allowed the performance of transfemoral TAVI in the majority of patients with smaller iliofemoral arteries, related to sheath size reduction; (2) transfemoral TAVI with both the SAPIEN XT and SAPIEN prostheses was associated with a high device success rate and similar periprocedural and short-term outcomes in high-risk elderly patients; and (3) the new-generation SAPIEN XT valve has the same short-term performance as the SAPIEN prosthesis.
The large sheath diameter required for valve implantation with the SAPIEN prosthesis was the most important limitation of this technique, requiring surgical cut-down for transarterial access in all patients. Indeed, about 40% of eligible patients could not be treated with a transfemoral approach using this valve, and underwent transapical implantation. The introduction of the SAPIEN XT prosthesis has dramatically improved the possibility of transfemoral implantation. In our series, the rate of transfemoral approach increased from 61.4% with the SAPIEN to 91.1% with the SAPIEN XT prosthesis. The requirement for a smaller iliofemoral diameter, the low risk of major adverse events, and the favourable performance of the SAPIEN XT prosthesis dramatically extended the clinical application for transfemoral TAVI, which can now be performed without surgical cut-down for transarterial access using pre-closing vascular devices.
To the best of our knowledge, there are few reports evaluating the SAPIEN XT prosthesis. The first study was published in 2009 by Webb et al., and reported favourable short-term outcomes in three patients [11] . Very recently, a single-centre observational study comparing the SAPIEN XT (n = 54) and SAPIEN (n = 66) prostheses in 120 patients who underwent transfemoral TAVI has been reported by Mussardo et al. [12] . They observed that the SAPIEN XT valve had the same short-term performance as the SAPIEN prosthesis, but was associated with a three-fold lower risk of major vascular complications (11.1% vs 33.3%; relative risk 0.40, 95% confidence interval 0.28-0.57; P = 0.004). Other complications, such as stroke, AKI, myocardial infarction and bleeding were similar, although there was a trend for a lower transfusion rate in the SAPIEN XT group [12] . Interestingly, the results of our observational study are close to those reported by Mussardo et al. as per the device success rate and 30-day performance, both similarly high with the two prostheses. However, we did not observe a significant reduction in major vascular complications with the SAPIEN XT. However, using similar VARC definitions, the incidence of major vascular events with SAPIEN XT was close to that reported by Mussardo et al. (8.1% vs 11.1% [12] ). In our experience, all major vascular events were actually related to failure of vascular closure devices, without any aortic dissection or iliofemoral rupture. In contrast, we reported a lower rate of major vascular complications using the SAPIEN valve as compared to their study (7.7% vs 33.3% [12] ). This discrepancy may be related, in their study, to the initial learning curve, less stringent patient selection and/or a higher incidence of preexistent peripheral arterial disease. Indeed, in our registry, we did not include patients without CT screening to assess the suitability for a transfemoral approach.
The main limitations of this study are its observational design and lack of randomization. A randomized comparison of the SAPIEN XT and SAPIEN prostheses has recently been required by the US Food and Drug Administration. However, when the SAPIEN XT was introduced in France, the SAPIEN valve became commercially unavailable. Furthermore, this prospective study reflects a single-centre experience on a relatively limited number of patients. We excluded TAVI patients treated before May 2006 with another approach (compassionate procedures or anterograde cases); other delivery systems (Retroflex 1 and 2); and a different screening process (no CT angiography) in order to optimally compare the two devices in patients with similar clinical evaluations. Finally, patients treated with the SAPIEN XT prosthesis had a lower risk profile than those treated using the SAPIEN prosthesis. However, indications of TAVI have been restricted to inoperable and high-surgical risk patients, and all decisions were made by the medicosurgical team.
Conclusions
Short-term safety and performance analysis of the latest generation SAPIENT XT balloon-expandable valve seems very similar to the previous generation. However, transfemoral implantation is possible more often, related to sheath size reduction. The Edwards SAPIEN XT prosthesis might facilitate the expansion of transfemoral TAVI in the future.
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